Efficacy, Safety, and Tolerability of Etravirine With and Without Darunavir/Ritonavir or Raltegravir in Treatment-Experienced Patients: Analysis of the Etravirine Early Access Program in the United States. Journal of Acquired Immune Deficiency Syndrome, 53(5): 614-618.
Author:
Appelbaum J, Bellman P, Gathe J, Gottlieb MS, Hoogstoel A, Laleari J, Nijs S, Ryan R, Sension M, Towner W, Van Solingen-Ristea R, Witek J, Wohlfeiler M
This website uses cookies to improve your experience. We’ll assume you’re ok with this, but you can opt-out if you wish. [cookie_settings] [cookie_button]